@article{f2e89f5995014789b7015f1ea22e8cf7,
title = "Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease",
keywords = "Parkinson's disease, genetics, movement disorders, neurogenetics",
author = "Ortega, \{Roberto Angel\} and Mark Groves and Anat Mirelman and Alcalay, \{Roy N.\} and Deborah Raymond and Sonya Elango and Helen Mejia-Santana and Nir Giladi and Karen Marder and Bressman, \{Susan B.\} and Rachel Saunders-Pullman",
note = "Funding Information: Funding This study was funded by the Michael J Fox Foundation for Parkinson{\textquoteright}s research and the National Institute of Neurological Disorders and stroke (NINDs-K02Ns073836). Funding Information: Competing interests sBB and rs-P have received consulting fees from Denali Therapeutics Inc. rNA has received consulting fees from Denali, Biogen and Genzyme/sanofi. NG serves as a member of the Editorial Board for the Journal of Parkinson{\textquoteright}s Disease. He serves as consultant to sionara, Accelmed, Teva, NeuroDerm, IntecPharma, Pharma2B, Denali and Abbvie. He receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures at Teva, UCB, Abbvie, sanofi-Genzyme, Bial and Movement Disorder society. NG received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program and the Israel science Foundation as well as from Teva NNE program, Biogen, LTI, and Pfizer.",
year = "2019",
month = jul,
day = "1",
doi = "10.1136/jnnp-2018-319364",
language = "אנגלית",
volume = "90",
pages = "843--844",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "7",
}
SDG 3 Good Health and Well-being